



## **Agenus to Present at the Jefferies 2016 Healthcare Conference**

June 2, 2016

LEXINGTON, Mass.--([BUSINESS WIRE](#))--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Garo H. Armen, Ph.D., Chairman and CEO, and Robert B. Stein, M.D., Ph.D., President, Research & Development, will present a corporate overview at the Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9<sup>th</sup> at 9:30am ET.

### **Webcast Information**

The live and archived webcast of the presentation will be accessible from the Company's website at [www.agenusbio.com/webcast](http://www.agenusbio.com/webcast). Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived replay will be available on the Agenus website for one month following the conference.

### **About Agenus**

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach for the discovery, development and manufacture of monoclonal antibodies that modulate targets of interest. In addition, the Company's cancer vaccine program includes three proprietary platforms focused on individualized and off-the-shelf vaccines uniquely designed for each patient. Agenus' broad portfolio of novel checkpoint and other immuno-modulatory monoclonal antibodies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. The Company has formed collaborations with Merck and Incyte to discover and develop multiple checkpoint antibodies. For more information, please visit [www.agenusbio.com](http://www.agenusbio.com); information that may be important to investors will be routinely posted on our website.

### **Contact:**

Agenus Inc.

Michelle Linn, 781-674-4541

[michelle.linn@agenusbio.com](mailto:michelle.linn@agenusbio.com)

or

Media:

BMC Communications

Brad Miles, 646-513-3125

[bmiles@bmccommunications.com](mailto:bmiles@bmccommunications.com)